- Record: found
- Abstract: not found
- Article: not found
Treatment of muscle‐invasive and advanced bladder cancer in 2020
August 07 2020
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Most cited references15
- Record: found
- Abstract: not found
- Conference Proceedings: not found
Abstract CT112: Durvalumab + tremelimumab in patients with metastatic urothelial cancer
Arjun Vasant Balar, Amit Mahipal, Enrique Grande … (2018)
- Record: found
- Abstract: not found
- Article: not found
Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients (pts) with chemotherapy-refractory metastatic urothelial carcinoma (mUC) either naïve (n) or refractory (r) to checkpoint inhibitor (CPI).
Rosa Nadal, Amir Mortazavi, Mark M. Stein … (2018)
- Record: found
- Abstract: not found
- Article: not found
A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC).
Jianjun Gao, Arlene O. Siefker-Radtke, Neema Navai … (2019)